Reducing the Risk of Coronavirus
In previous outbreaks (SARS, H1N1 and MERS) the World Health Organisation highlighted that aerosol generating procedures increased risk of pathogen transmission.
The Intensive Care society have issued similar advice in their COVID-19 communication stating aerosol generating procedures should be avoided: 2019-nCOV – Critical Care Society advice.
The World Federation of Societies of Anaesthesiologists (WFSA) list nebulisation amongst aerosol generating procedures:
“Aerosol generating procedures include intubation, extubating, bronchoscopy, airway suction, high frequency oscillatory ventilation, tracheostomy, chest physiotherapy, nebulizer treatment. These procedures should be performed on the COVID-19 patient only when the benefits outweigh the risks, and when adequate PPE and staff preparation is available.”
Spirale®: Reduce the Risk of Pathogen Transmission
Spirale® drug delivery system can help to reduce the risk of pathogen transmission.
Spirale® is an alternative to jet nebulisation during bronchodilator therapy. This collapsible volumising chamber is designed to deliver micro-drug particles from a Metered Dose Inhaler (MDI). The product is intended to remain in the breathing circuit, therefore removing the risk of environmental contamination in the clinical setting.
AquaVENT VT®: Breathing Circuits with BioCote® Protection
Many of our breathing circuits are supplied with BioCote®.
The impact of BioCote® on the Coronavirus is yet to be confirmed – however, previous case studies of influenza A H1N1 virus demonstrate that a BioCote® protected surface was less contaminated with the virus.
BioCote® is an antimicrobial silver additive which limits the number of microbes on the surface of the breathing circuit, protecting it from microbial colonisation.
BioCote® technology can help reduce the risk of bacterial/microbial cross-contamination and has been proven to reduce bacteria/microbes on products by up to 99.5% in two hours OR 99.99% in 24hrs. BioCote® protection can help protect both patients and staff in the hospital environment.
Read more about the benefits of BioCote®.
Bacterial Viral Filtration
We supply bacterial/viral filters that provide an effective barrier against viruses, preventing cross contamination between patients, respiratory equipment and the clinical environment.
Current COVID-19 viable particles are thought to be sized between 0.1 and 0.2micron in mass median diameter (100 to 200nm). These particles are significantly larger in comparison to the proven effectiveness, under test, of the Pharma Systems filter range for filtration efficiency against, for example Hepatitis C (55-65nm). It follows then that filtration of COVID-19 will be effective when using the Pharma Systems electrostatic filters and filter/HMEs.
Pharma Systems (Knivsta, Sweden) electrostatic bacterial viral filters and electrostatic bacterial viral HME filters are manufactured and validated in conformance with industry standard BS EN ISO 23328-1:2008 Breathing system filters for anaesthetic and respiratory use. Salt test method to assess filtration performance.